Reversal of a potent investigational anticoagutant: Idraparinux with recombinant factor VIIa

被引：9

作者：

Dao, A ^{[1
]}

Tuan, B ^{[1
]}

Carlson, N ^{[1
]}

机构：

[1] Calif Pacific Med Ctr, Dept Internal Med, San Francisco, CA 94115 USA

来源：

AMERICAN JOURNAL OF MEDICINE | 2005年 / 118卷 / 10期

关键词：

D O I：

10.1016/j.amjmed.2005.04.025

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1172 / 1173

页数：2

共 5 条

[1] The pharmacology and management of the vitamin K antagonists [J].

Ansell, J ;

Hirsh, J ;

Poller, L ;

Bussey, H ;

Jacobson, A ;

Hylek, E .

CHEST, 2004, 126 (03) :204S-233S

[2] Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers [J].

Bijsterveld, NR ;

Vink, R ;

van Aken, BE ;

Fennema, H ;

Peters, RJG ;

Meijers, JCM ;

Büller, HR ;

Levi, M .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 124 (05) :653-658

[3] Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide [J].

Herbert, JM ;

Hérault, JP ;

Bernat, A ;

van Amsterdam, RGM ;

Lormeau, JC ;

Petitou, M ;

van Boeckel, C ;

Hoffmann, P ;

Meuleman, DG .

BLOOD, 1998, 91 (11) :4197-4205

[4] Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran [J].

Schulman, S ;

Wåhlander, K ;

Lundström, T ;

Clason, SB ;

Eriksson, H .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (18) :1713-1721

[5]

Weitz Jeffrey I, 2004, Hematology Am Soc Hematol Educ Program, P424

← 1 →